Ofichem, a leading European Contract Development and Manufacturing Organisation (CDMO) focused on high-quality active pharmaceutical ingredients (APIs) and integrated drug development, has acquired Meribel Pharma Solutions’ Uppsala site in Sweden. This strategic move strengthens Ofichem’s early-phase, IP-driven drug substance development capabilities, particularly in the small-molecule space.

The Uppsala facility, formerly part of Recipharm and known as OT Chemistry, employs 20 people and specialises in small-scale, early-phase development. Its technical strengths span both traditional small molecules and emerging therapeutic modalities such as antibody-drug conjugates (ADCs), oligonucleotides, and PROTACs. The acquisition significantly expands Ofichem’s non-GMP service offerings for biotech innovators.

“This acquisition is a strategic building block in Ofichem’s broader transformation,” said Dr. Weite H. Oldenziel, CEO and owner of Ofichem. “We aim to serve innovative biotech firms with agile, early-stage development solutions, and this site gives us the expertise and platform to realise that vision.”

The move signals Ofichem’s evolving focus—from a heritage in generics and mid-sized pharma to a deeper investment in high-value services for emerging biotech companies. The Uppsala site will work in close coordination with Ofichem’s GMP-certified manufacturing plant in Ter Apel, the Netherlands, enabling a smooth transition from early R&D to commercial-scale production.

With this acquisition, Ofichem also gains access to a portfolio of over 40 biotech and mid-sized pharma clients, strengthening its market presence across the Nordic region.

“We’re pleased to welcome the Uppsala team to Ofichem and expand our capabilities and geographic footprint,” said Alessia Cogotti, Managing Director, Ofichem. “This strengthens our commitment to support clients from early discovery through to manufacturing.”

Bruce Vielle, CEO of Meribel Pharma Solutions, added, “Ofichem is an ideal partner who shares our values and customer-first approach. This transition will ensure long-term value for clients and continuity for ongoing projects.”

The site will be integrated into Ofichem’s matrix structure under unified leadership in operations, quality, R&D, and business development. Ofichem also plans future expansion into larger-scale GMP manufacturing in Europe and North America to broaden its early-stage development network.